Wnt/beta-catenin modulation: A promising frontier in chronic kidney disease management.

IF 2.1 4区医学 Q3 PHARMACOLOGY & PHARMACY Fundamental & Clinical Pharmacology Pub Date : 2024-08-05 DOI:10.1111/fcp.13031

Shubhangi Saxena, Neha Dagar, Vishwadeep Shelke, Bhupendra Puri, Anil Bhanudas Gaikwad

{"title":"Wnt/beta-catenin modulation: A promising frontier in chronic kidney disease management.","authors":"Shubhangi Saxena, Neha Dagar, Vishwadeep Shelke, Bhupendra Puri, Anil Bhanudas Gaikwad","doi":"10.1111/fcp.13031","DOIUrl":null,"url":null,"abstract":"Background: Being amongst the leading factors of death and distress, chronic kidney disease (CKD) has affected around 850 million people globally. The Wnt/β-catenin axis is vital for maintaining kidney homeostasis, from nephron generation to overall management. The β-catenin growth factor is typically not expressed in the adult kidney; however, its expression is found to increase under stress and injury conditions. It is categorised as canonical and non-canonical based on β-catenin availability, which mounts promising targets for ameliorating CKD. Hence, modulation of the Wnt/β-catenin signalling for CKD management is of utmost relevance.Objectives: The primary aim of this review is to highlight the significance of targeting Wnt/β-catenin signalling for CKD management.Methods: The literature review regarding the role of Wnt/β-catenin signalling and therapies modulating it in CKD was conducted using PubMed, Scopus, Science Direct and Google Scholar.Results: The current review summarises the pharmacological therapies modulating the Wnt/β-catenin axis in CKD, building upon promising preclinical studies to establish a foundation for clinical studies in the future.Conclusion: Wnt/β-catenin signalling is the evolution's most conserved pathway, which plays a pivotal role in CKD progression. Therapies modulating Wnt/β-catenin signalling have emerged as effective means for alleviating CKD.","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fundamental & Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/fcp.13031","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Being amongst the leading factors of death and distress, chronic kidney disease (CKD) has affected around 850 million people globally. The Wnt/β-catenin axis is vital for maintaining kidney homeostasis, from nephron generation to overall management. The β-catenin growth factor is typically not expressed in the adult kidney; however, its expression is found to increase under stress and injury conditions. It is categorised as canonical and non-canonical based on β-catenin availability, which mounts promising targets for ameliorating CKD. Hence, modulation of the Wnt/β-catenin signalling for CKD management is of utmost relevance.

Objectives: The primary aim of this review is to highlight the significance of targeting Wnt/β-catenin signalling for CKD management.

Methods: The literature review regarding the role of Wnt/β-catenin signalling and therapies modulating it in CKD was conducted using PubMed, Scopus, Science Direct and Google Scholar.

Results: The current review summarises the pharmacological therapies modulating the Wnt/β-catenin axis in CKD, building upon promising preclinical studies to establish a foundation for clinical studies in the future.

Conclusion: Wnt/β-catenin signalling is the evolution's most conserved pathway, which plays a pivotal role in CKD progression. Therapies modulating Wnt/β-catenin signalling have emerged as effective means for alleviating CKD.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Wnt/beta-catenin 调节：慢性肾病治疗的一个前景广阔的领域。

背景：慢性肾脏病（CKD）是导致死亡和痛苦的主要因素之一，已影响到全球约 8.5 亿人。Wnt/β-catenin 轴对维持肾脏的平衡至关重要，包括肾小球的生成和整体管理。β-catenin生长因子通常不在成人肾脏中表达，但在压力和损伤条件下，其表达会增加。根据β-catenin的可用性，可将其分为典型和非典型两类，这为改善慢性肾脏病提供了有希望的靶点。因此，调节 Wnt/β-catenin 信号对治疗 CKD 至关重要：本综述的主要目的是强调靶向 Wnt/β-catenin 信号对治疗 CKD 的重要意义：方法：使用 PubMed、Scopus、Science Direct 和 Google Scholar 对 Wnt/β-catenin 信号在 CKD 中的作用以及调节 Wnt/β-catenin 信号的疗法进行文献综述：本综述总结了在 CKD 中调节 Wnt/β-catenin 轴的药理学疗法，以前景看好的临床前研究为基础，为未来的临床研究奠定基础：结论：Wnt/β-catenin 信号是进化过程中最保守的通路，在 CKD 的进展中起着关键作用。调节 Wnt/β-catenin 信号的疗法已成为缓解 CKD 的有效手段。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Fundamental & Clinical Pharmacology 医学-药学

CiteScore

5.30

自引率

6.90%

发文量

111

审稿时长

6-12 weeks

期刊介绍： Fundamental & Clinical Pharmacology publishes reports describing important and novel developments in fundamental as well as clinical research relevant to drug therapy. Original articles, short communications and reviews are published on all aspects of experimental and clinical pharmacology including: Antimicrobial, Antiviral Agents Autonomic Pharmacology Cardiovascular Pharmacology Cellular Pharmacology Clinical Trials Endocrinopharmacology Gene Therapy Inflammation, Immunopharmacology Lipids, Atherosclerosis Liver and G-I Tract Pharmacology Metabolism, Pharmacokinetics Neuropharmacology Neuropsychopharmacology Oncopharmacology Pediatric Pharmacology Development Pharmacoeconomics Pharmacoepidemiology Pharmacogenetics, Pharmacogenomics Pharmacovigilance Pulmonary Pharmacology Receptors, Signal Transduction Renal Pharmacology Thrombosis and Hemostasis Toxicopharmacology Clinical research, including clinical studies and clinical trials, may cover disciplines such as pharmacokinetics, pharmacodynamics, pharmacovigilance, pharmacoepidemiology, pharmacogenomics and pharmacoeconomics. Basic research articles from fields such as physiology and molecular biology which contribute to an understanding of drug therapy are also welcomed.